Largest artery in the body
POPULARITY
95 episodes with aortic
13 episodes with aortic
24 episodes with aortic
15 episodes with aortic
12 episodes with aortic
13 episodes with aortic
7 episodes with aortic
6 episodes with aortic
9 episodes with aortic
4 episodes with aortic
13 episodes with aortic
6 episodes with aortic
7 episodes with aortic
14 episodes with aortic
4 episodes with aortic
3 episodes with aortic
6 episodes with aortic
5 episodes with aortic
8 episodes with aortic
5 episodes with aortic
6 episodes with aortic
3 episodes with aortic
4 episodes with aortic
3 episodes with aortic
3 episodes with aortic
4 episodes with aortic
3 episodes with aortic
2 episodes with aortic
3 episodes with aortic
8 episodes with aortic
6 episodes with aortic
3 episodes with aortic
3 episodes with aortic
3 episodes with aortic
2 episodes with aortic
3 episodes with aortic
Morning Glory With Huia! Today Huia had Aortic come in for Fancy New Band who played their new single ! Thank you to NZ On Air! Thank you to The Tuning Fork!
Huia had Aortic come in for Fancy New Band today! Aortic smashed out an awesome set of experimental, genre merging, alternative rock tunes! Thanks to NZ On Air!
LBCT: Four-year Hemodynamic Outcomes with An Intra-annular, Self- Expandable Transcatheter Aortic Valve
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Bo Yang, a cardiovascular and thoracic surgeon at the University of Michigan Health in Ann Arbor, Michigan, USA, about aortic root enlargement. Chapters 00:00 Intro 02:37 JANS 1, WhatsApp for Patients 08:27 JANS 2, DCD Heart Transplant 11:07 JANS 3, TIGHT K Trial 13:18 JANS 4, RecoverHeart Calculator 15:57 Video 1, Self Constructed Valve 18:52 Video 2, MVR Sandwich Technique 20:43 Video 3, Distal Coronary Anastomosis Podcast 23:04 Dr. Yang, Annular Enlargement 36:31 Upcoming Events 37:26 Closing They explored Dr. Yang's participation in a debate regarding the use of aortic root enlargement for the majority of patients, addressing the opposing views against root enlargement and discussing the percentage of patients who undergo this procedure. The conversation also covered important topics such as the mean gradient dropping and the lifelong management of aortic valve disease. They emphasize the importance of maximizing the initial valve size for optimal outcomes. Additionally, Dr. Yang shared insights on his Y-incision technique, highlighting its advantages and effectiveness. They also examined whether this technique increases the length of the surgical procedure. Joel also highlights recent JANS articles on exploring the use of instant messaging groups in the postoperative period for pectus excavatum patients, a multicenter retrospective study comparing DCD heart transplantation in Europe and the United States, six-month outcomes of a trial of potassium supplementation thresholds after cardiac surgery, and determining the individualized probability of myocardial recovery. In addition, Joel explores self-constructed tubular heart valve using bovine pericardium for surgical treatment of tricuspid valve endocarditis, mitral valve repair using the sandwich technique for symmetrical bileaflet prolapse, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Elan Burton about distal coronary anastomosis. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned Exploring the Use of Instant Messaging Groups in the Postoperative Period for Pectus Excavatum Patients A Comparison of DCD Heart Transplantation in Europe and the United States: A Multi-Centre, Retrospective Study Six-Month Outcomes of a Trial of Potassium Supplementation Thresholds After Cardiac Surgery Determining the Individualized Probability of Myocardial Recovery: The Multicenter RecoverHeart Calculator CTSNet Content Mentioned Self-Constructed Tubular Heart Valve Using Bovine Pericardium for Surgical Treatment of Tricuspid Valve Endocarditis Mitral Valve Repair Using the Sandwich Technique for Symmetrical Bileaflet Prolapse The Atrium: Distal Coronary Anastomosis Other Items Mentioned Career Center CTSNet Events Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Andrea Steely, an Assistant Professor of Cardiac Surgery in the Division of Cardiothoracic Surgery at the University of Utah Health, Salt Lake City, UT, USA, about aortic surgery and long-term patient follow-up. Chapters 00:00 Intro 01:43 New CTSNet Website 02:36 AATS 2026 09:15 EJCTS News 10:15 Video 1, Left Ventriculotomy 10:51 Video 2, 3-Vessel TECAB 12:24 Video 3, AV Disease in Young Patients 13:14 Andrea Steely, Aortic Surgery & Follow-Up 29:14 Upcoming Events They discussed the critical importance of educating both patients and surgeons about aortic disease, and the most effective strategies for follow-up care after aortic surgery. The conversation also covered testing genetic factors and stabilizing the aortic arch. They also explored reintervention and the importance of a multidisciplinary follow-up approach. Additionally, they addressed topics such as lung cancer screening, the training of non-MDs to evaluate screening charts, and the development of an aortic pathology sheet for each patient. In addition, Joel explores an underutilized approach for closing multiple apical ventricular septal defects, robotic-assisted three-vessel minimally invasive coronary artery bypass, and a presentation from Emile Bacha on the "Surgical Management of Aortic Valve Disease in Young Patients." Before closing, Joel highlights upcoming events in CT surgery. CTSNet Content Mentioned 1. Left Ventriculotomy: An Underutilized Approach for Closing Multiple Apical Ventricular Septal Defects 2. Robotic-Assisted Three-Vessel Minimally Invasive Coronary Artery Bypass 3. SCTS 2026 | Surgical Management of Aortic Valve Disease in Young Patients Other Items Mentioned 1. How to Navigate the New CTSNet Website 2. Career Center 3. CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
LBCT: Repeat Intervention After Failed Transcatheter Aortic Valve Implantation (TAVI): Outcomes of Redo TAVI Versus Surgical Explantation
This episode covers: Cardiology This Week: A concise summary of recent studies Genetics and genetic testing in HCM Asymptomatic aortic valve stenosis Statistics Made Easy: Mediation analysis Host: Wilfried Mullens Guests: JP Carpenter, Caroline Coats, Marc Dweck Want to watch that episode? Go to: https://esc365.escardio.org/event/2564 Want to watch that extended interview on asymptomatic aortic valve stenosis, go to: https://esc365.escardio.org/event/2564?resource=interview Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Caroline Coats has declared to have potential conflicts of interest to report: in the last 5 years, consultant/advisor to Bayer, Bristol Myers Squibb, Cytokinetics, Sanofi, Roche Diagnostics. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Wilfried Mullens Guest: Marc Dweck Want to watch that extended interview on https://esc365.escardio.org/event/2564?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2564 Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
LBCT: Transfemoral J-Valve System for Chronic Aortic Regurgitation: Initial Post-market In-Hospital Experience In 236 Patients
In this podcast, Francis Marchlinski, MD, Deputy Editor of JACC: Clinical Electrophysiology, discusses a large multicenter study evaluating the incidence and clinical significance of aortic regurgitation following mapping and ablation of ventricular arrhythmias in the aortic cusps and commissures. Drawing on contemporary data from four high‑volume centers, the paper provides important reassurance regarding the safety of aortic cusp ablation, demonstrating that clinically significant aortic regurgitation is rare and infrequently progressive. Dr. Marchlinski highlights the key findings, procedural considerations, and implications for everyday practice in ventricular arrhythmia ablation.
In this episode, we'll focus on the final sections of the guideline, which deal with rupture, trauma, and post-operative complications. These are scenarios where decisions are often made under time pressure, evidence is limited, and outcomes can be profoundly affected by organisation of care, experience, and judgement.Guests:Prof. Anders WanhainenDr. Carlota Fernández-Prendes Prof. Athanasios Katsargyris
Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826261424814
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Frank Tamru, author of Power: A Memoir and owner of Frank Tamru Consultants LLC, about aortic valve technology throughout the years. Chapters 00:00 Intro 01:51 New Website Preparation 02:53 AATS 2026 Overview 11:59 Video 1, Robotic Right-Sided MIDCAB 13:08 Video 2, Extra-Anatomic IAA Repair 14:29 Video 3, Double-Decker Procedure 16:38 Video 4, Aortic Disease Awareness 19:53 Video 5, Robotic Culmen in Situs Inversus 21:30 Frank Tamru, Aortic Valve Technology 35:32 Upcoming Events 36:03 Closing They explored Tamru's professional background and involvement with heart surgeons and cardiovascular leaders. The conversation covered various topics, including heart valves and the evolution of open-heart centers. They also discussed the advancements in aortic valve replacement technologies and the critical role of surgeons as decision-makers in the field. Additionally, Frank shared his experience as the founding publisher of the Asian Cardiovascular and Thoracic Annals. In addition, Joel explores a robotic-assisted right-sided minimally invasive coronary artery bypass for anomalous origin of the right coronary artery, a transdiaphragmatic aorto-supraceliac extra-anatomic bypass for interrupted aortic arch with collateralizations, double-decker procedure for partial anomalous pulmonary venous connection, robotic-assisted right upper segmentectomy (culmen) in situs inversus totalis, and an interview with Gareth Owens and Dr. Ben Youdelman on Think Aorta and aortic disease awareness. Before closing, Joel highlights upcoming events in CT surgery. CTSNet Content Mentioned 1. Robotic-Assisted Right-Sided Minimally Invasive Coronary Artery Bypass for Anomalous Origin of the Right Coronary Artery 2. A Transdiaphragmatic Aorto-Supraceliac Extra-Anatomic Bypass for Interrupted Aortic Arch With Collateralizations 3. Double-Decker Procedure for Partial Anomalous Pulmonary Venous Connection 4. Think Aorta and Aortic Disease Awareness: An Interview With Gareth Owens and Dr. Ben Youdelman 5. Robotic-Assisted Right Upper Segmentectomy (Culmen) in Situs Inversus Totalis Other Items Mentioned 1. Power: A Memoir 2. Website Maintenance Alert! 3. The Lifeline 4. Career Center 5. CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
Welcome back to the ESVS Podcasts. This is Suzanne Stokmans, and you are listening to part 2 of the Q&A series on the ESVS 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases.In this episode, we move from the general principles discussed in part 1 to disease-specific management. We'll focus on acute thoracic aortic syndromes, chronic type B aortic dissection, and degenerative descending thoracic and thoraco-abdominal aortic aneurysms, conditions that make up a large part of daily aortic practice, where decision-making is often nuanced and time-critical.Full names of guests:Prof. Anders WanhainenDr. Carlota Fernández Prendes Prof. Athanasios Katsargyris.
In today's episode, the first of this three-part series, we will discuss the opening section of the guideline: service standards and general considerations. Before moving to specific disease entities or operative strategies, the guideline deliberately starts with the fundamentals — how care should be organised, how patients should be assessed, and which general principles should guide our decision making.Full names of guests:Prof. Anders WanhainenDr. Carlota Fernández Prendes Prof. Athanasios Katsargyris.
In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Jwan Naser from The Mayo Clinic in Rochester, Minnesota, USA. They discuss her study on asymptomatic aortic regurgitation, which suggests it may be less benign than previously believed. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/early/2025/11/17/heartjnl-2025-326643
Commentary by Dr. Jian'an Wang.
Commentary by Dr. Shinichi Shirai.
Commentary by Dr. Jian'an Wang.
With Morton Kern, VA Long Beach and University of California, Irvine, California - USA and Arnold Seto, VA Long Beach and University of California, Irvine, California - USA. Link to European Heart Journal paper Link to European Heart Journal editorial
How common are aortic dissections in Asia, and why do some patients appear to present nearly a decade earlier than in Western cohorts? Laurence Bertrand speaks with Dr. Peter Robless, founder of vascular surgery at the national university hospital of Singapore and former President of the Asian Society for Vascular Surgery, about Asian epidemiology, treatment approaches, and evolving endovascular practice.
Host: Darryl S. Chutka, M.D. Guest: George Wang, M.D. Bicuspid aortic valve is a relatively common congenital heart disease. It can be associated with other genetic disorders such as Turner's Syndrome or exist as an isolated entity. In most cases, patients with a bicuspid aortic valve are initially asymptomatic; however later in the course, they may develop symptoms related to a subsequent aortic stenosis or regurgitation. It's also associated with a dilated ascending aorta with potential rupture if unrecognized. Therefore, it's in the patient's best interest to diagnose the condition as early as possible. What are the early symptoms and when should we suspect the patient may have a bicuspid aortic valve? What type of surveillance should be performed and when is surgery indicated? These are some of the questions I'll be asking my guest, Dr. George Wang, a cardiologist in the Department of Cardiovascular Medicine at the Arizona Campus of the Mayo Clinic as we discuss “Bicuspid Aortic Valve Disease”. Mayo Clinic Talks: Heart Health | Mayo Clinic School of Continuous Professional Development Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development
Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
In this episode, we review the high-yield topic of Traumatic Aortic Disruption from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
BUFFALO, NY — December 12, 2025 — A new #research paper was #published in Volume 17, Issue 11 of Aging-US on November 14, 2025, titled “Methylglyoxal-induced glycation stress promotes aortic stiffening: putative mechanistic roles of oxidative stress and cellular senescence.” The study was led by first authors Parminder Singh of the Buck Institute for Research on Aging and Ravinandan Venkatasubramanian of the University of Colorado Boulder, with senior contributions from corresponding authors Pankaj Kapahi (Buck Institute for Research on Aging) and Zachary S. Clayton (University of Colorado Boulder and University of Colorado Anschutz Medical Campus). The researchers investigated how methylglyoxal (MGO), a toxic byproduct that builds up in blood vessels with age or metabolic dysfunction like diabetes, contributes to artery stiffening. Their findings are especially important to aging and diabetes-related cardiovascular risk. Aortic stiffening, which reduces the flexibility of the body's largest artery, is a key predictor of cardiovascular disease in older adults. The research team used young and aged mice to study how MGO affects vascular health. In young mice, chronic exposure to MGO increased aortic stiffness by 21%. However, when treated with Gly-Low, a supplement containing natural compounds such as nicotinamide and alpha-lipoic acid, this stiffening was completely prevented. Gly-Low also reduced the buildup of MGO and its harmful byproducts, particularly MGH-1, in both blood and tissue. “Aortic stiffness was assessed in vivo via pulse wave velocity (PWV) and ex vivo through elastic modulus.” The research showed that MGO's damage goes beyond structural changes. It also caused the endothelial cells that line blood vessels to enter senescence, a state in which cells stop dividing and begin releasing inflammatory signals. This led to lower levels of nitric oxide, a molecule essential for blood vessel relaxation. In human vascular cells in lab culture, Gly-Low reversed these aging-like changes and restored nitric oxide production. In older mice, which naturally develop stiffer arteries, Gly-Low treatment during four months significantly reduced stiffness and lowered MGO and MGH-1 levels. This suggests that Gly-Low may help slow or even reverse vascular aging by reducing glycation stress. The study also identified the glyoxalase-1 pathway as a critical mechanism. This is a natural detox system that helps clear harmful molecules like MGO. Gly-Low appeared to boost this pathway. When the pathway was chemically blocked, Gly-Low's protective effects disappeared, confirming its role in the process. Overall, the findings highlight glycation stress as a modifiable contributor to vascular aging. The results suggest that natural compound-based therapies, like Gly-Low, may offer a potential strategy to protect arteries from age- and diabetes-related damage. DOI - https://doi.org/10.18632/aging.206335 Corresponding authors: Pankaj Kapahi - pkapahi@buckinstitute.org; Zachary S. Clayton - Zachary.Clayton@cuanschutz.edu Abstract video: https://www.youtube.com/watch?v=i_rtq8eIb8c Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Aortic Regurgitation: Beyond the Valve Guest: Vidhu Anand, M.B.B.S. Host: Kyle Klarich, M.D. In this episode of Mayo Clinic's “Interviews With the Experts,” Dr. Klarich and Dr. Anand discuss evolving approaches to assessing left ventricular remodeling in chronic aortic regurgitation. Dr. Vidhu Anand discusses research showing that LV volumes, global longitudinal strain, and myocardial fibrosis can detect dysfunction earlier than traditional guideline thresholds. Listeners can expect to better understand the role of multimodality imaging, extra valvular involvement, and practical steps echocardiographers can take to optimize AR assessment. Topics Discussed: What imaging markers help detect early myocardial dysfunction in AR, and how do they assist in risk stratification? Guidelines traditionally focus on LV dimensions and ejection fraction for surgical decision-making in AR. Is there any data that guidelines may not be capturing patients at the optimal time? Is there a role of multimodality imaging in AR? What practical steps can a sonographer or echocardiographer today to bring their AR assessment closer to what your research suggests is optimal? Please reference Dr. Anand's research article(s) here: https://pubmed.ncbi.nlm.nih.gov/39545891/ https://pubmed.ncbi.nlm.nih.gov/33253815/ https://pubmed.ncbi.nlm.nih.gov/39218370/ Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251344842
Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251336314
Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251344848
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Fraser Sutherland, a consultant cardiac surgeon at Ross Hall Hospital and the Golden Jubilee National Hospital, Scotland, about the world's first transcervical robotic aortic valve replacement (AVR) procedures. Chapters 00:00 Intro 02:30 JANS 1, CABG After 60 Years 13:53 JANS 2, Endovascular Arch Repair 16:45 JANS 3, Impact of Age on ARR 18:47 JANS 4, Anterior Mediastinal Teratomas 20:28 Career Center 21:02 Video 1, RUL Without Dissecting SPV 22:58 Video 2, Replacement w Double Patch Repair 23:53 Video 3, TAVR & SAVR Removal w LVOR 24:47 Dr. Sutherland Interview 45:26 Closing They discuss the history and evolution of these cases, along with the preclinical work that led to this innovative technique. Dr. Sutherland addresses initial challenges such as the uniportal incision, the transcervical retractor system, and enhancing dexterity by incorporating a robotic system. They also detail the first clinical case, including postoperative outcomes and the importance of maintaining safety for the patient. Additionally, they explore the benefits for patients undergoing this procedure and its future potential. Furthermore, Dr. Sutherland provides insights into the procedural steps and key aspects of the procedure. Joel also highlights recent JANS articles on coronary artery bypass grafting 60 years after its debut, endograft design options and worldwide results for endovascular arch repair, the impact of age on aortic root replacement, and a multicenter retrospective study on if subxiphoid thoracoscopic surgery is safe and feasible for the treatment of anterior mediastinal teratomas. In addition, Joel explores a multiportal approach for robotic right upper lobectomy without dissecting the superior pulmonary vein, aortic and mitral replacement with double patch repair, and TAVR and SAVR removal with left ventricular outflow reconstruction. JANS Items Mentioned 1.) Coronary Artery Bypass Grafting: 60 Years After Its Debut 2.) Endovascular Arch Repair: Endograft Design Options and Worldwide Results 3.) The Impact of Age on Aortic Root Replacement 4.) Subxiphoid Thoracoscopic Surgery Is Safe and Feasible for the Treatment of Anterior Mediastinal Teratomas: A Multicentre Retrospective Study CTSNet Content Mentioned 1.) Robotic Right Upper Lobectomy Without Dissecting the Superior Pulmonary Vein: A Multiportal Approach 2.) Aortic and Mitral Replacement With Double Patch Repair 3.) TAVR and SAVR Removal With Left Ventricular Outflow Reconstruction Other Items Mentioned 1.) World's First Transcervical Robotic AVR Procedures Successfully Performed in 4 Cleveland Clinic Patients 2.) Resident Video Competition 3.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani 4.) Career Center 5.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
Recorded at the BASICS Pre-Hospital Care Conference at Sketchley Grange, this episode explores one of the most experimental tools in civilian trauma care — the abdominal aortic and junctional tourniquet. Dr Ed Barnard joins us to discuss why this device was developed, how it works, and where it might — just might — save lives when all other options have failed. The conversation traces the problem of non-compressible haemorrhage, the leading cause of potentially survivable trauma death. Conventional limb tourniquets, pelvic binders and packing can't reach these deep bleeding sites. The AAJT offers a radical alternative: external aortic compression to buy a few crucial minutes until surgical control or REBOA is possible. Ed explains the mechanism — an inflatable, ratcheted belt that can occlude the aorta or major junctional vessels — and the evidence so far. Laboratory and volunteer data show that it can stop flow, but pain and tissue ischaemia make it difficult to tolerate for long. Clinical experience remains limited to small case series, mostly in military or research settings, and no human trials yet demonstrate a survival benefit. The discussion is candid about risk and realism. The AAJT is a last-resort device, to be used only within strict governance, with clear time limits and immediate plans for definitive haemorrhage control. It's not something you reach for on a normal shift — it's something you might need once in a career, and only if every other option has failed. Ed shares insights from ongoing research, including its potential role as a bridge to REBOA, and the governance frameworks that should surround any trial use. The episode ends with a look to the future: how civilian and military collaboration might refine indications, training, and data collection for this rare but potentially life-saving intervention. Surgeon Captain Ed Barnard Surgeon Captain Ed Barnard is a Consultant in Emergency Medicine at Addenbrooke's Hospital, Cambridge, and a Professor of Emergency Medicine with the Defence Medical Services. He also serves with East Anglian Air Ambulance as a HEMS doctor (having had many years as a BASICS responder). His academic work focuses on prehospital and military trauma care, with a portfolio spanning clinical trials, blood product innovation, and trauma system development. Ed's academic work focuses on improving survival from catastrophic bleeding, particularly non-compressible and junctional haemorrhage. He has published and presented widely on trauma resuscitation, traumatic cardiac arrest, and the evolving role of devices such as the abdominal aortic and junctional tourniquet (AAJT) and REBOA. He is a co-author of the 2025 BMJ Military Health systematic review examining the utility of the AAJT-S in military practice. He is also an experienced educator, contributing to trauma training for BASICS, HEMS, and Defence Medical Services, and continues to combine clinical work with research aimed at translating lessons from military to civilian trauma care. About BASICS: The British Association for Immediate Care (BASICS) is a UK charity uniting clinicians dedicated to pre-hospital emergency medicine. Founded in 1977, it supports regional immediate-care schemes, delivers national training, and hosts the annual BASICS Pre-Hospital Care Conference, bringing together experts in trauma, retrieval, and critical care — like this conversation with Dr Ed Barnard.
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Single- Versus Dual-Access Transcatheter Aortic Valve Implantation Using Balloon-Expandable Platform: A Propensity Score Matching Study.
Dr. Adam Power, co-founder and Chief Medical Officer at Front Line Medical Technologies, shares his fascinating journey from a background in vascular surgery to developing COBRA-OS, a groundbreaking device for hemorrhage control. He discusses the challenges and milestones in bringing this life-saving technology to market, the impact of the device in trauma and emergency care, and innovative future applications, including its unexpected use in non-traumatic cardiac arrest. Guest links: https://frontlinemedtech.com/ Charity supported: Canadian Cancer Society Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com. PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical EPISODE TRANSCRIPT Episode 064 - Dr. Adam Power [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm excited to introduce you to my guest, Dr. Adam Power. Dr. Power is a leader in innovative medical devices for trauma and emergency care that is committed to lowering the barriers and bleeding control and resuscitation. Dr. Power was instrumental in the development of COBRA-OS, drawing on his unique clinical viewpoint and expertise to ensure utmost patient safety and assist with the company's global expansion. In addition to his current role as co-founder and Chief Medical Officer at Front Line Medical Technologies Incorporated, Dr. Adam Power is a vascular surgeon in the division of vascular surgery at Western University, which he joined in the fall of 2012, and he is involved in all aspects of academics and clinical care. Also, Front Line was just named the 2025 Medical Device Technology Company of the Year, so I definitely wanted to highlight that too. All right. Well, thank you so much for being here today, Adam. I'm so delighted to speak with you. [00:01:55] Dr. Adam Power: Yes, it's a pleasure to be here. Thank you. [00:01:57] Lindsey Dinneen: Of course. Well, I'd love if you would start by sharing a little bit about yourself, your background, and what led you to what you're doing today. [00:02:05] Dr. Adam Power: Sure, I'd love to. So I'm a Canadian. I grew up on the east coast of Canada and was always interested in science and math and those types of things. I think, importantly, I grew up with an identical twin brother as well. So we really didn't know what we wanted to do with our lives, and ultimately we're good in science and math and ended up in medicine. And then both of us, when we got into medicine, we weren't sure exactly what we wanted to do in medicine, and ultimately both of us became surgeons. He became a urology surgeon, and I became a vascular surgeon, where we joke that we're both plumbers. I deal with the red stuff and he's the yellow stuff. But I did my initial medical school out on the east coast of Canada and then I did my general surgery training, which also involved trauma training, and then did a Master's of Bioscience Enterprise, which was basically biotech business from the University of Cambridge in the UK. When I finished my general surgery training, I continued on and did vascular surgery training at Mayo Clinic down in the US, and since that time after graduating from there, I've been at Western University in London, Ontario, Canada, for the past 13 years practicing as a vascular surgeon and an academic vascular surgeon. But when I was here at Western, I was always interested in innovation. I filed my first patent as a resident way back when, and have filed many over the years. But ultimately, if I was ever gonna see anything that came outta my head and was actually used in a patient or I could actually use in a patient, I figured I'd have to do it. I knew that I couldn't do it by myself. And so, I was very fortunate to meet my co-founder Dr. Asha Parekh. She's a PhD, biomedical engineer, extremely smart jack of all trades, and we teamed up now about eight years ago. We met here at Western, teamed up and really took an idea right out of our heads and patented it and raised money for it, prototyped it, brought it all through the regulatory steps to approvals, built a quality system and ultimately got it out onto the market in Canada, US, Europe, now Australia, and more to come. So the commercialization piece is what we've been focusing on over the past three years. And it's been really fun, but very exhausting but very rewarding as well. I think I'll stop there because I've been blathering on, but... [00:04:39] Lindsey Dinneen: No, it's fantastic. I really appreciate it. Plus, it's really fun to hear about your trajectory and so, okay, so you've teased us a little bit about this company of yours and this innovation of yours. Can you now share a little bit more about that and the development of it over time? [00:04:55] Dr. Adam Power: Yes, of course. Well, I mean, thing that we recognized early on is, and I'll just explain how I normally explain it, is if you have bleeding, it's a hemorrhage control device. And so if you have bleeding in your extremities, then you can often either put pressure on it or you can put a tourniquet on it. The problem when you have internal bleeding in the torso is that you can't actually put direct pressure on it, and there's no tourniquet that necessarily works for intraabdominal, intrathoracic bleeding. And when people bleed to death before coming to hospital, I mean, they're bleeding in these areas. You can empty almost your entire blood volume into your chest or into your abdomen. And this does account for a significant number of fatalities in all environments, basically in the trauma environment. That's military, that's pre-hospital, that's any time that that people are bleeding from internal organs. And so, because this is such a problem, the old fashioned way to fix it is to open up someone's chest and put a clamp on the aorta. So what does that do? Is it basically above the clamp, keeps blood flowing. The remaining blood in the body keeps blood flowing to the brain and the heart, keep you alive. And then below the clamp, it stops sort of the hemorrhaging from the spleen or the liver or whatever. So there's two things going on. One above the clamp and two below the clamp. But opening up somebody's chest in, you know, side of the road or in the emergency department really is impossible. You need highly skilled people like vascular surgeons like myself to be able to do this. And even if we were at the side of the road, we don't have the resources available to keep a patient alive. So there is this idea that we could do this minimally invasively, sort of accomplish this through minimally invasive means. And this, the idea of doing REBOA, which is an acronym-- Resuscitative Endovascular Balloon Occlusion of the Aorta-- came into being. This was probably 15, 20 years ago now. It wasn't necessarily a new idea. It had been done since the Korean War. There was somebody actually put a balloon up into someone's aorta to stop bleeding, but it came back again and was starting to be used a little bit more because. And so really the idea is to, through the femoral artery in your groin where you can feel a pulse, you introduce initially a sheath, which is your access point, and then you place the device up through the sheath, up into the aorta and inflate a balloon in the aorta. So instead of an external clamp, it's an internal balloon clamp that keeps blood flowing above the balloon and stops the blood flowing from below the balloon. Initially these devices were as big as my baby finger, like they were massive. And so if you put them in and you took it out, there was a big hole in the artery, had to cut down on the artery and repair the artery. But as it got more and more advanced and technology advanced, they become smaller and smaller. So that's really where we came in. The initial devices were 12 French, about the size of my baby finger. And then it advanced to Seven French and all of a sudden Seven French-- and these are diameter, French sizes are basically diameter-- and so when it went from 12 to seven French, now we could start doing it through the skin without actually cutting down on the artery. But that Seven French size was still very large and you're putting this in the hands of people that don't do this all the time. And so, we had the idea to bring it down even further now to Four French. And so this is essentially the size of an IV. And so you put a tiny little IV in somebody's femoral artery. And lots of different people can do that. And then you advance the device up in, inflate the balloon and you can magically occlude the aorta. In our first study that we did, the first inhuman study, we averaged about just over a minute to occlude someone's aorta, which was really fast to be able to get that amount of control that quickly. So that, that was really been the advancement is to decrease the access size, make this whole procedure simpler so that so that we can essentially save more lives. [00:09:08] Lindsey Dinneen: Okay, so thank you so much for sharing a little bit about that. Can you tell me about the beginnings of this innovation and how you brought it to market? Because it's really wonderful to hear all the success, and I'm so excited to hear that it's spreading, you have presence all over the place now. But you know, that's not an easy pathway. And I'm curious if you could walk us through a little bit about that decision to go, "You know what? We have a solution to a known problem, we can make this happen." And then how did you actually go about doing that? [00:09:42] Dr. Adam Power: Yeah. I think, I mean, I make it sound fairly straightforward, like a nice story, but it certainly was not that. I mean, we were very lucky I would say, that we had a lot of great advisors and mentors that we figured that we try not to fail early, fail fast. We wanted to make this one as successful as possible. So before we made any decision, we often would consult our mentors. And I'm a surgeon. I like to shoot first, ask questions later. My partner is not. And so I think we, we strike an excellent balance between not just the engineering and clinical side of things, but also from driving a business forward, getting all the information, but helping to get decisions made and moving forward. You know, starting out, we really had to choose the right sort of fit for what we wanted to pursue. We like to say it checked all the boxes. It checked all the boxes as far as even where we are. We're in Canada, we're not in a tech triangle where there's tons of funding opportunities. We knew we would be limited from a funding perspective, so we couldn't choose something that necessarily required a hundred million dollars to start up. So, you know, we had this device that we knew that we could fundraise for it. And then once it was fundraised, it was simple enough that we could get it manufactured. We chose to go the OEM route for the original equipment manufacturer, so we didn't have to build a manufacturing facilities ourselves. And then really from there, and building a quality system in the regulatory, we did work with a lot of consultants, that was both positive and negative experience. We had great consultants. We had not so great consultants. But really what our our goal was, is to learn the process ourselves. And so there's always manuals for things, even from the FDA perspective. They give out great documentation about what is supposed to go into an FDA application. And we dug into that. We really tried to understand. We did not trust anyone. That's one of my rules in surgery is, "don't trust anyone, not even myself." So we really didn't trust our consultants, and we tried to double check and triple check everything so that we didn't make mistakes. And of course, we did make mistakes and had to go back to the drawing board a few times. But as much as we wanted to get this out there, we really did wanna learn the process and know the process because ultimately we're the ones that are responsible to the patients in the end, and we needed to make sure that we had a handle on each and every step of the way. We, of course, because of that, were maybe not as quick as we could have been but in other places we became more efficient because, as we learned the process, getting feedback back and doing it right the first time, it really made a difference. So. [00:12:39] Lindsey Dinneen: Yeah, absolutely. Of course. Yeah, and I appreciate you going into a little bit more of the nitty gritty details 'cause it is so fun to hear the success stories, but of course, as you go along, there's that pathway to success. And it's helpful to understand that yeah, it's gonna be potentially a long road, sometimes windy, sometimes weird, but at the same time that it is possible. So as you look to the future with your company, what are you thinking of in terms of the future? Are you going to continue down this pathway and continue with iterations of this device? Are you thinking of new devices to introduce as well? Or, what are your thoughts for the future? [00:13:18] Dr. Adam Power: Yeah. And I have to be very careful what I say here, obviously. I can share generically what our thoughts are. We love this. Ultimately there was no better feeling than to use-- I mean, I've used my device to save a patient. And, you know, I would say that Asha, who's my co-founder, she cares. I'm a physician, but she cares about the patients just as much as I do, as does everyone in our company, which is really quite rewarding. But the future, what does the future hold? We really want this to get to everywhere. Yes, we're in lots of different countries ,have commercialized really all around the globe, but we really wanna go deeper into a lot of these geographies and really help as many people as possible. We realize that we can't do it on our own and are gonna need help. And so that's, we're in a growth phase right now of our company and we're looking for strategic collaboration. We're looking for those opportunities to deepen our ties and in all the different geographies. That being said, we are inventors and of course we have an idea every day about what we could improve on. But as far as the pipeline goes for our company, we are focusing on some very specific up and coming applications that we hope to have in the next couple of years. And I also wanna say that, I talked about trauma and bleeding, but the more exciting side of aortic occlusion has really been the applications. And you'd think, okay, it makes sense for trauma to be able to stop blood flow and stop bleeding. But some of our recent successes have been through postpartum hemorrhage. And there is this really, terrible condition called placenta accreta, where the placenta grows into the uterus and when you deliver the baby either by C-section or by delivery, and then the placenta attempts to be delivered, it tears, and you can have torrential bleeding. And, and so our device is being used in these women who are pregnant when inflicted with this condition and helping to decrease blood transfusions, helping to save a mother's life. So that's been really amazing. And then next on the horizon is strangely there's, it's not even a bleeding application. We've done some research and there's research going on globally about using aortic, minimally invasive aortic occlusion for non-traumatic cardiac arrest. And so if, which is really, again, it's like, "Oh my gosh, does this thing do everything? It might make your supper tonight if you're not careful." So it, so what happens there is that if somebody drops dead basically in front of you, and you start CPR, if you start pushing on their chest and pushing on their heart, you're pushing blood to the whole body. And the way you get someone back to life is if you can get the heart muscle oxygenated again. So if you put an aortic occlusion balloon up close to the heart, every time you push, you're directing blood right into the coronary arteries and right into the brain as well. And so what we're seeing is that there's increased return of spontaneous circulation rates when you do this with CPR. And there are different trials around the world that if this shows that there's an increase in survival or in better neurological survival, this will be the first time that we've really changed the script on cardiac arrest since advanced cardiac life support came out many years ago. So this, again, is very exciting for a simple device to be able to make that much impact in all these different areas. So, you know, we have a lot to focus on right now, even growing into the future because some of these, like cardiac arrest, are quite early on. So we don't wanna lose sight of this great original product, but we do think all the time about different pipeline ideas that could help other patients. [00:17:18] Lindsey Dinneen: Yeah, but, and to your point, even the amazing other use cases for this incredible device, like you said-- maybe it's gonna make us dinner next-- but the idea being that, who knows? I mean, there's so much more to discover even now, which makes me excited just to think about how many more use cases you could have for it and how many more people you could save. So, speaking of that, are there any stories that kind of stand out to you, moments that you've had where, you know, either through your day job, so to speak, being a vascular surgeon, but also being the co-founder of this company that really sort of affirmed to you that, "You know what? I am in the right place at the right time, in the right industry." Just those moments that really stick with you. [00:18:05] Dr. Adam Power: Yeah, I mean, it obviously all stems back to the patient and what patients are impacted. And I remember, the first time that the device was used at our hospital, one of the radiologists called me in and said, " We need to use one of these balloon occlusion devices for a patient that's been in an accident." And so I went in and I said, "I actually have the device that my partner and I created. We can use this for the patient." And so we started using it for the lady that was involved in a very serious accident, had a pelvic fracture, and she was a Jane Doe at that particular time. She was anonymous. And anyway, we noticed that she had actually had some vascular surgery done based on her angiograms, and I leaned over and I-- so she was sedated, but she was awake-- I said, "Have you had vascular surgery? Who's your vascular surgeon?" And she said, "It's Dr. Power. He's such a nice man." And so I was actually helping one of my patients. That was pretty crazy. [00:19:04] Lindsey Dinneen: Oh. [00:19:05] Dr. Adam Power: Also from my hospital, when I heard one of my junior residents was able to save someone's life. So, you know, junior residents are often good, but they're not trained surgeons. And so to have a simplistic device that one of my residents could actually place and help someone, that's pretty amazing too. There's also been times where like even the postpartum hemorrhage, we hear the first cases in the States of saving mother and baby. That's pretty incredible. Or that we donated some devices to the Ukraine conflict as well, and we heard that it saved some soldiers' lives as well. And there's different military groups that, that use our device and save soldiers. So it's all back to the patient. And hearing those success stories and hearing about somebody alive because of this particular device, because of all this effort that we've put in. I mean, it's really makes it worthwhile. It sounds kind of corny, but as a surgeon, I can help one person at a time, but as somebody involved in industry and medical device industry, I don't even have to be there. You know, this device can help long after I'm gone. The tricky part of it, being the Chief Medical Officer is, I usually only have to worry about my patients. Now I have to worry about everybody worldwide and the device being used. That was a little hard to wrap my head around initially, but yeah. [00:20:28] Lindsey Dinneen: Yeah, of course. But the ripple, the ripples, the impact that you get to have because of this device and because of your diligence getting it to market, because it isn't an easy path, and that's incredible. So thank you for doing the work that you're doing. That's not easy and it's very appreciated. This is incredible. So, yeah. So, okay. When you were growing up, let's say 8-year-old, Adam-- you know, you're having a good time doing whatever you like to do-- could you possibly have pictured yourself where you are now? [00:21:08] Dr. Adam Power: No, I don't think so. I mean, I, I. I came from a very small, like, small upbringing and, you know, in my family I had absolutely lovely family members, but they really, apart from my aunt, they weren't overly educated. And so I really didn't know what it took to be successful in life, really. I had work ethic from my parents, that's for sure. And so that's what they bred into me. And all I knew is that I was gonna work as hard as I could, and I figured that as long as I keep working-- and I was lucky to have some brains as well-- then I figured things would fall into place. They honestly haven't fallen into place exactly how I pictured them as I grew older and what it would look like. But I'm certainly thankful for where I am right now, and what is the next five years or 10 years gonna look like? I have no idea. And I guess I just don't even picture it. I have goals, but I also know that those goals change depending on circumstances. And you need, as I'm growing into middle age-- I think I'm beyond middle age now-- I'm thinking about midlife crisis and things like that. I get into philosophy and there's like telic and atelic things and so, it's sounds, again, it's about the path and the journey. It's not about the ultimate goal because, having reached a lot of these successes, that good feeling lasts for maybe a day or half a day. And you think you know, I spent all these years coming with the, with our device, getting our device to market and getting FDA approval and like, oh my gosh, like, you'd think, I'd feel so great about that. And it did. It felt great, but you wake up the next day and you gotta keep going. So you have to enjoy the journey and that's really what it's the wisdom that comes with age is trying to enjoy the journey as much as possible and not focus too much beyond that. [00:23:09] Lindsey Dinneen: Yeah. Yeah, and I think that's really good advice too, in that it is because the daily life isn't usually all the celebration and successes. I mean, that does happen and those are good moments, but because the vast majority of our life is spent on the journey component of it, and going through those peaks and valleys, it is important to find something you love and feel that you can make an impact in. So I'm so thankful that this is what you've chosen to do. So pivoting the conversation a little bit just for fun, imagine that you're to be offered a million dollars to teach a masterclass on anything you want. Could be within your industry, but it doesn't have to be. What would you choose to teach? [00:23:55] Dr. Adam Power: And would that mean that I was an expert in it? [00:23:58] Lindsey Dinneen: Well, certainly if you're getting paid a million dollars, somebody has decided you aren't an expert at it. How about that? [00:24:05] Dr. Adam Power: Okay. Well. Can I pretend like I'm an expert in it? There's something that I really love, but I'm not I'm probably not an expert in it. It would be, I would teach a masterclass in DJing. Isn't that strange? I know it's so random. [00:24:21] Lindsey Dinneen: Oh my goodness! Tell me more! [00:24:23] Dr. Adam Power: Well, I mean, I love music. I've, I grew up playing lots of sports and never was involved in music. And, and I've always appreciated music and art, but I was never able to do it. And, you know, growing up I did love sort of all types of music and then even electronic music and it just somehow talked to me. So I started DJing electronic music basically when I was around med school and have always loved it now, and when I was over in England, I DJ'ed on the campus radio and also DJ'd in a club. It was really fun and it sounds pretty silly to be talking about this when I have these other things that are on the go. But honestly, being able to share space with other human beings these days, and actually having a good time and having it not be stressful and having it be only, you know, everybody's wishing others to have a good time. There's not many people that go out sort of dancing into electronic music that are thinking bad things about other people. Really they're just out for a good time. And so being able to steer that whole music and scene is pretty awesome. And I do love it. And I don't DJ as much as I used to, but I still do different events, usually Christmas parties for the operating room. I'll do the typically wedding sort of DJ, but then they always, 'cause they know me, they let me do an hour long electronic set, which is like hardcore electronic. But then I go back to the regular stuff. But I would want to teach a masterclass in DJing. [00:25:56] Lindsey Dinneen: That is awesome. How exciting. Oh my gosh, I love that. And I think you're right. Music brings us together and it's a wonderful way to, to share a little bit of joy. [00:26:07] Dr. Adam Power: Yeah. [00:26:08] Lindsey Dinneen: Yeah. Okay. And then how do you wish to be remembered after you leave this world? [00:26:15] Dr. Adam Power: I, so number one is I don't, again, with my midlife crisis, I've actually been trying to eliminate my ego as much as possible. And so when people talk about legacy, it actually gives me the hives these days to be quite honest, because I don't like that because I think you're focused a lot on yourself. In my opinion, a lot of legacy is all about you. The way that I would wanna be remembered, though, is truly that I was kind and compassionate to everyone that I met, and that I stood for something, and that I left the world a better place. [00:26:57] Lindsey Dinneen: Yeah, those are wonderful things to want to be remembered for, absolutely. And then final question, what is one thing that makes you smile every time you see or think about it? [00:27:09] Dr. Adam Power: My kids. My son Kai and my daughter Saoirse. They are the light of my life. And I, you would think that with how busy I am ,you know, those things would deprioritize, but they truly are the one thing in my life that makes me smile when I get up in the morning. [00:27:30] Lindsey Dinneen: Oh, that's wonderful. Well, that is absolutely incredible. I loved getting to meet you and speak with you a little bit today. Thank you so much for sharing about your journey. Thank you for sharing about your incredible device and your bits of wisdom along the way. The idea of we've gotta enjoy the experience, the path, the journey. And I just really appreciate you spending some time with us. So thank you for everything you're doing to change lives for a better world. [00:27:59] Dr. Adam Power: Oh, well, thank you for giving me the opportunity to speak with you. It was absolutely lovely chatting with you today. [00:28:05] Lindsey Dinneen: Wonderful. Well, thank you again so much. Thank you also to listeners who are tuning in, and if you're as inspired as I am, I would love it if you would share this episode with a colleague or two and we'll catch you next time. [00:28:20] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.
Host: Darryl S. Chutka, M.D. Guests: Christopher Francois, M.D. The risk of thoracic aortic dissection increases as the diameter of the aorta widens. A diameter greater than 5 cm is associated with an increased risk of dissection in the general population. Patients with Marfan Syndrome have defective connective tissue and dissection commonly occurs with diameters less than 5 cm. Other health conditions associated with aortic dilation and potential dissection include Ehlers Danlos and those with bicuspid aortic valves. It therefore becomes extremely important to accurately assess the aorta. Fortunately, we now have a variety of imaging tools available and several of these tools are relatively new. My guest for today's podcast is Dr. Christopher Francois, from the Department of Diagnostic Radiology at the Mayo Clinic and he'll bring us up to date regarding the most recent imaging techniques as we continue our series on vascular medicine. We'll discuss who's at risk for an aortic aneurysm, when some of the more traditional imaging is indicated and when we should consider some of the newer imaging tools. Mayo Clinic Talks: Vascular Medicine Series | Mayo Clinic School of Continuous Professional Development Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts
The Impact of Gender on Outcomes of Transcatheter Aortic Valve Implantation Between Self-Expanding Valve and Balloon-Expandable Valve
A silent danger lurks within the descending thoracic aorta. While most Type B aortic dissections are managed medically, up to half of these patients will either require life-saving surgery or die within just five years. So how do we separate those who will quietly recover from those on the edge of catastrophe? How do we protect the spinal cord, bowel, and limbs from the devastating consequences of malperfusion? Join the University of Michigan Department of Vascular Surgery as they tackle the high-stakes decisions behind managing this unpredictable disease—where timing is critical, interventions are evolving, and lives hang in the balance. Hosted by the University of Michigan Department of Vascular Surgery: · Robert Beaulieu, Program Director · Frank Davis, Assistant Professor of Surgery · Luciano Delbono, PGY-5 House Officer · Andrew Huang, PGY-4 House Officer · Carolyn Judge, PGY-2 House Officer Learning Objectives: 1. Discuss general approach to diagnosis and management of TBAD. 2. Identifying high-risk features in uncomplicated TBAD and understanding their role in determining the need for surgical management. 3. Review endovascular techniques for managing malperfusion of the limbs, viscera, and spinal cord and discuss associated decision making. References: Authors/Task Force Members, Czerny, M., Grabenwöger, M., Berger, T., Aboyans, V., Della Corte, A., Chen, E. P., Desai, N. D., Dumfarth, J., Elefteriades, J. A., Etz, C. D., Kim, K. M., Kreibich, M., Lescan, M., Di Marco, L., Martens, A., Mestres, C. A., Milojevic, M., Nienaber, C. A., … Hughes, G. C. (2024). EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ. The Annals of Thoracic Surgery, 118(1), 5–115. https://doi.org/10.1016/j.athoracsur.2024.01.021 de Kort, J. F., Hasami, N. A., Been, M., Grassi, V., Lomazzi, C., Heijmen, R. H., Hazenberg, C. E. V. B., van Herwaarden, J. A., & Trimarchi, S. (2025). Trends and Updates in the Management and Outcomes of Acute Uncomplicated Type B Aortic Dissection. Annals of Vascular Surgery, S0890-5096(25)00004-4. https://doi.org/10.1016/j.avsg.2024.12.060 Eidt, J. F., & Vasquez, J. (2023). Changing Management of Type B Aortic Dissections. Methodist DeBakey Cardiovascular Journal, 19(2), 59–69. https://doi.org/10.14797/mdcvj.1171 Lombardi, J. V., Hughes, G. C., Appoo, J. J., Bavaria, J. E., Beck, A. W., Cambria, R. P., Charlton-Ouw, K., Eslami, M. H., Kim, K. M., Leshnower, B. G., Maldonado, T., Reece, T. B., & Wang, G. J. (2020). Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. Journal of Vascular Surgery, 71(3), 723–747. https://doi.org/10.1016/j.jvs.2019.11.013 MacGillivray, T. E., Gleason, T. G., Patel, H. J., Aldea, G. S., Bavaria, J. E., Beaver, T. M., Chen, E. P., Czerny, M., Estrera, A. L., Firestone, S., Fischbein, M. P., Hughes, G. C., Hui, D. S., Kissoon, K., Lawton, J. S., Pacini, D., Reece, T. B., Roselli, E. E., & Stulak, J. (2022). The Society of Thoracic Surgeons/American Association for Thoracic Surgery Clinical Practice Guidelines on the Management of Type B Aortic Dissection. The Annals of Thoracic Surgery, 113(4), 1073–1092. https://doi.org/10.1016/j.athoracsur.2021.11.002 Papatheodorou, N., Tsilimparis, N., Peterss, S., Khangholi, D., Konstantinou, N., Pichlmaier, M., & Stana, J. (2025). Pre-Emptive Endovascular Repair for Uncomplicated Type B Dissection—Is This an Option? Annals of Vascular Surgery, S0890-5096(25)00007-X. https://doi.org/10.1016/j.avsg.2025.01.003 Trimarchi, S., Gleason, T. G., Brinster, D. R., Bismuth, J., Bossone, E., Sundt, T. M., Montgomery, D. G., Pai, C.-W., Bissacco, D., de Beaufort, H. W. L., Bavaria, J. E., Mussa, F., Bekeredjian, R., Schermerhorn, M., Pacini, D., Myrmel, T., Ouzounian, M., Korach, A., Chen, E. P., … Patel, H. J. (2023). Editor's Choice - Trends in Management and Outcomes of Type B Aortic Dissection: A Report From the International Registry of Aortic Dissection. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery, 66(6), 775–782. https://doi.org/10.1016/j.ejvs.2023.05.015 Writing Committee Members, Isselbacher, E. M., Preventza, O., Hamilton Black Iii, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., Collins, T. J., DeAnda, A., Fanola, C. L., Girardi, L. N., Hicks, C. W., Hui, D. S., Jones, W. S., Kalahasti, V., … Woo, Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 80(24), e223–e393. https://doi.org/10.1016/j.jacc.2022.08.004 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
A 17 yo male presents for follow up on a “fainting” episode that occurred during football practice at the end of a running exercise. He states, “I do not know what happened. We finished a set of running sprints and next thing I knew, I was on the ground.” He denies injury from the event and history of prior episodes. His physical examination reveals a crescendo-decrescendo systolic murmur heart best at the apex, increasing in intensity with position change from supine to standing position. This most likely represents: A. Mitral regurgitation B. Physiologic murmur C. Hypertrophic cardiomyopathyD. Aortic stenosis Visit fhea.com to learn more!
So there's this new Star Trek Podcast - and, btw, I'm terrified of death. Plus, we have a conversation about the Runabout, speaking of fear of death.
In today's VETgirl online veterinary continuing education podcast, we interview Dr. Missy Carpentier, DACVIM (Neurology) of Minnesota Veterinary Neurology on aortic thromboembolism (ATE) in dogs. While this seems like a "cardiology" or emergency critical care problem, ATE is a classic presentation for the "down" dog. That said, ATE in dogs is entirely different from cats—in everything from signalment and clinical presentation to prognosis. Tune in to learn all things ATE, including how we diagnose and treat this hypercoagulable disease, and what the prognosis is.
In today's VETgirl online veterinary continuing education podcast, we interview Dr. Missy Carpentier, DACVIM (Neurology) of Minnesota Veterinary Neurology on aortic thromboembolism (ATE) in dogs. While this seems like a "cardiology" or emergency critical care problem, ATE is a classic presentation for the "down" dog. That said, ATE in dogs is entirely different from cats—in everything from signalment and clinical presentation to prognosis. Tune in to learn all things ATE, including how we diagnose and treat this hypercoagulable disease, and what the prognosis is.
Drs. Rick Ferraro and Sneha Nandy discuss ‘Diagnosis of ATTR Cardiac Amyloidosis' with Dr. Venkatesh Murthy. In this episode, we explore the diagnosis of ATTR cardiac amyloidosis, a condition once considered rare but now increasingly recognized due to advances in imaging and the availability of effective therapies. Dr. Venkatesh Murthy, a leader in multimodality imaging, discusses key clinical and laboratory features that should raise suspicion for the disease. We also examine the role of nuclear imaging and genetic testing in confirming the diagnosis, as well as the importance of early detection. Tune in for expert insights on navigating this challenging diagnosis and look out for our next episode on treatment approaches for cardiac amyloidosis! Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Diagnosis of Transthyretin amyloid cardiomyopathy 1. Recognizing the Red Flags – ATTR cardiac amyloidosis often presents with subtle but telling signs, such as bilateral carpal tunnel syndrome, low-voltage ECG, and a history of lumbar spinal stenosis or biceps tendon rupture. If you see these features in a patient with heart failure symptoms, think amyloidosis! 2. “Vanilla Ice Cream with a Cherry on Top” – On strain echocardiography, apical sparing is a classic pattern for cardiac amyloidosis. While helpful, it's not foolproof—multimodal imaging and clinical suspicion are key! 3. Nuclear Imaging is a Game-Changer – When suspicion for cardiac amyloidosis is high à a positive PYP scan with SPECT imaging (grade 2 or 3 myocardial uptake) in the absence of monoclonal protein (ruled out by SPEP, UPEP, and free light chains) is diagnostic for ATTR amyloidosis—no biopsy needed! 4. Wild-Type vs. Hereditary? Know the Clues – Older patients (70+) are more likely to have wild-type ATTR, while younger patients (40s-60s), especially those with neuropathy and a family history of heart failure, should raise suspicion for hereditary ATTR. Genetic testing is crucial for distinguishing between the two. Note that some ATTR variants may predispose to a false negative PYP scan! 5. Missing Amyloidosis = Missed Opportunity – With multiple disease-modifying therapies now available, early diagnosis is critical. If you suspect cardiac amyloidosis, don't delay the workup—early treatment improves outcomes! Notes - Diagnosis of Transthyretin amyloid cardiomyopathy What clinical features should raise suspicion for ATTR cardiac amyloidosis? ATTR cardiac amyloidosis is underdiagnosed because symptoms overlap with other forms of heart failure. Red flags include bilateral carpal tunnel syndrome (often years before cardiac symptoms), low-voltage ECG despite increased LV wall thickness, heart failure with preserved ejection fraction (HFpEF) with a restrictive pattern, and history of lumbar spinal stenosis, biceps tendon rupture, and/or peripheral neuropathy, including possible autonomic dysfunction (e.g., orthostatic hypotension). Remember: If an older patient presents with heart failure and unexplained symptoms like neuropathy or musculoskeletal issues, think amyloidosis! What is the differential diagnosis for a thick left ventricle (LVH) and how does ATTR amyloidosis fit into it? Hypertension: Most common cause of LVH, typically with a history of uncontrolled high blood pressure. Aortic stenosis: May present with concentric LVH. Hypertrophic cardiomyopathy (HCM): Genetic disorder typically presenting with asymmetric LVH, especially in younger patients. Infiltrative cardiomyopathy: Often due to amyloidosis, sarcoidosis,
Ronda Hazell's story started in June 2024 when an echocardiogram showed she had a dilated ascending aorta (a dilation is a bulge where the diameter of the aorta gets bigger when it is more than 1.5 times normal size it is called an aneurysm). This is a life-threatening medical condition because larger aneurysms can rupture or dissect. Aortic disease is linked to problems with the aortic valve of the heart. Ronda has regular check-ups with a cardiologist to monitor her heart and aneurysm size. Finding good medical help was difficult but it is there. Having the issues she's been facing discussed will help more of women find good medical diagnosis and help. Heart disease for women is different. SewDoItForHeart25 is a way to showcase people in the sewing community who integrate hearts into their projects to raise awareness that heart disease for women exists and is different. If you are able, consider supporting this podcast through our patreon account. There are 3 new tiers to choose from to support SewOver50's only podcast. Every podcast is free and the archive is gradually being uploaded on to the podcast YouTube channel. Sound with permission by Kaneef on YouTube. SewOver50 intersects with all communities. SewOver50 where we are so over ageism. Our focus is the sewing talent each person shares on social media and providing recognition of their willingness to share their skills whether a beginner or experienced sewist. Make sure you listen to your SewOver50 friends in our SewOver50 podcast archive.
Heart attacks & strokes are down, but guess what's rising? ⚡ Atrial fibrillation,
In this episode, we review the high-yield topic Aortic Regurgitation from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
The Reversing Heart Disease Summit 3.0 is now live! Register today to access expert insights on heart health: Reversing Heart Disease Summit. This week, Dr. Kahn explores new research on Lipoprotein(a) [Lp(a)], a topic he has long studied. He discusses recent findings on Lp(a)'s potential protective role in the liver and its link to calcific aortic stenosis, a condition affecting the aortic valve. Additional topics include new insights into long COVID and the potential role of nicotine, the benefits of the Prolon fasting-mimicking diet for gum health, and how hearing loss may contribute to cognitive decline—along with how diet might help. Dr. Kahn also breaks down the relationship between cardiac health and brain function (Life's Essential 8) and reviews another study confirming that statins may help protect against dementia. Plus, he shares a fascinating case study on the Kempner diet and its effects. Special thanks to our sponsor, Endurance Products. Use code KahnMD10 for a discount. You can also order Prolon at prolonlife.com/drkahn.
This week we review a work from the department of cardiology and department of cardiac surgery at Boston Children's Hospital on late hypertension in patients following coarctation repair. Late hypertension has been associated previously with late transverse aortic arch Z score but can this be predicted by the immediate postoperative transverse aortic arch Z score also? What factors account for late hypertension in the coarctation patient? Should more patients have their aorta repaired from a sternotomy? Dr. Sanam Safi-Rasmussen, who is a PhD candidate at Copenhagen University, shares her insights from a work she performed while a research fellow at Boston Children's Hospital. DOI: 10.1016/j.jtcvs.2024.08.049
Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Valerie: Hi Doctor Cabral, I have a quick question I hope you can help with. I often make 32oz smoothie bowls and usually eat half. But sometimes I eat the whole thing, and I end up with upper stomach pain and a feeling like the smoothie is coming back up for the rest of the day. It goes away after a few hours, but my stomach feels stretched and sensitive for a few days afterward. This only happens when I eat large amounts of smoothie, not with other foods, so I think it's the quantity. Do you think something else could be going on? Thanks so much for your answer! Angie: Hi Dr. Cabral,Thanks for your love for research in the health field. My husband was diagnosed with diabetes and wanting to help him naturally, I told him I would try out berberine and see if it gave me any reactions before he took it for diabetes. When I started taking it I noticed that I could tolerate more foods, like beans and other things that typically gave me a histamine reaction. It seemed to calm down my system. I would like to continue taking it so I can eat more foods without reactions, but I am hearing from the natural health community that it can kill off bifidobacteria. I only take one 500mg at lunch and one 500mg at dinner. My questions are 1. What does Berberine do that it allows me to eat more foods and 2. Is there any reputable research on long term use of Berberine? Lenny: Thank you so much for all your hard work and for taking the time to answer our questions. I'm a big fan of post-workout smoothies, and my go-to recipe includes banana, spinach, broccoli, blueberries, avocado, dates, protein powder, cacao, chia and linseeds, creatine, ashwagandha, stevia, coconut, and cacao nibs. I do feel a bit bloated afterward, but it's the best way for me to get all these healthy ingredients in. What are your thoughts on this smoothie combination? If it's not optimal, do you have any suggestions for improvements? Thanks again for your help! Christine: What Omega 3 gel caps do you recommend? Gine: Hi Dr. Cabral - I am seeking guidance on how to manage my husbands dx of a biscupid aortic valve with anyeurism of ascending aorta. Both his parents of this but no anyeurism at 65. My husband is 41 and we found out 2 years ago his anyeurism was 4.8cm, then last year went down to 4.5cm, now this month back to 4.8cm. If this is accurate with the rate of growth they will inevitably rec. surgery which of course we want to avoid. Is there anything you'd recommend that could possibly reduce the size of anyeurism, prevent further growth and avoid surgery? I have him on DNS, omegas, vit D, berberine+, mag & probiotic. My son was born with the bicuspid as well and I want to make sure I do everything in my power to set him up for success and hopefully avoid ever having an anyeurism. TYSM! Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3236 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
© 2020-2026 Ivy Podcast Discovery LLC
